The FDA approved a first drug–device product that uses a digital chip to monitor ingestion. This tracking technology could help address the costly problem of poor drug adherence in both medical practice and clinical trials, if it lives up to its promise… Click here to original publication. Fonte: 818 | DECEMBER 2017 | VOLUME 16…
Huntington’s breakthrough may stop disease
Click here to original publication. Fonte: Health and science correspondent, BBC News…
Drugs that made headlines in 2017
In 2017, cancer drugs once again dominated the news, with many of these medications making headlines for being the first of their kind to gain approval. Beyond cancer, drugs for inflammatory diseases also received attention, for both their successes and their failures. Fonte: VOLUME 23 | NUMBER 12 | DECEMBER 2017 NATURE MEDICINE Click here to original publication.…
First Approved Kinase Inhibitor for AML
Click here to original publication. Fonte: Cell 171, November 16, 2017 © 2017 Published by Elsevier Inc. 981…
FDA approves ‘trackable’ pill
The Abilify MyCite aripiprazole tablets – for treating schizophrenia and manic episodes – have an ingestible sensor embedded inside them that records that the medication has been taken. Fonte: BBC NEWS Click here to original publication.…
Spanish group defeats Shkreli in Chagas voucher race
The US Food and Drug Administration (FDA) approved for the first time a small-molecule drug to treat Chagas disease or American trypanosomiasis in children. The anti-parasitic benznidazole, has been around for over 40 years but until now it lacked an official go-ahead. Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 11 NOVEMBER 2017 Click here to original publication.…
Predictable response
On 25 January 2015, Chih-Ming Ho, a former aerospace engineer, waited anxiously in his office at the University of California, Los Angeles, for an e-mail that would potentially alter the fate of a group of patients at the local liver-transplant center. Fonte: VOLUME 23 | NUMBER 11 | NOVEMBER 2017 NATURE MEDICINE Click here to original publication.…
FDA approves antitoxin antibody
The FDA has approved Merck & Co’s bezlotoxumab to reduce the recurrence of Clostridium difficile infection, marking the first approval for a new approach to the treatment of bacterial infections. Unlike antibiotics, which kill pathogenic bacteria, bezlotoxumab is an antibody that mops up toxins that are released by C. difficile. Although antibiotics can control C. difficile, the infection recurs within weeks in around 25% of patients. In two phase III trials that tested bezlotoxumab in conjunction with standard of care…
Living therapeutics: Scientists genetically modify bacteria to deliver drugs
In 2004, Laurel Lagenaur was struck by a report from the United Nations showing that HIV was increasingly infecting women, who accounted for nearly half of the 38 million adults living with HIV worldwide1. Until then, researchers in the US had considered the disease to strike primarily men who had sex with men. As the director of research at Osel, a biotech start-up based in Mountain View, California, Lagenaur began to ponder ways to address the growing crisis. The company,…
Closing the deal
A checklist for negotiating robust licensing agreements. Universities have long been viewed as important to the economic and social well-being of their communities, but in recent years expectations have changed. Universities are now expected, increasingly even mandated, by governments and other funders of research to play a more active role in economic develop¬ment, especially by assisting in creating new companies, and ensuring that research fund¬ing eventually leads to products beneficial to the public. At the center of this activity is…